CGEN: רווח נקי למניה (EPS TTM) Compugen Limited

Compugen Ltd. ensures development stability through the diversification of biosubstance suppliers. The GURU.Markets terminal provides the EPS trend for the last 12 months, where this metric equals 0.37, confirming the asset's resilience. High market confidence is driven by major licensing contracts, while management's strategy relies on advanced computational methods for target discovery in immuno-oncology.

The efficiency of PVRIG antibody development and the monetization of its AI platform in the B2B sector determine the financial stability of Compugen Ltd. (CGEN). This indicator calculates the net profit allocated per share over a rolling year, allowing for an assessment of the real return on capital without distortions between reports. By analyzing the trend of earnings per share over the last 12 months, an investor can identify the growth stage or the risk of overpaying for the asset.